Search results
8 paź 2022 · Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022; 400:1213-1222. Full Text.
29 mar 2022 · The first two oral antivirals, molnupiravir and nirmatrelvir–ritonavir, are now becoming available in many countries. These medicines will be indicated to treat mild-to-moderate COVID-19 in non-hospitalised patients who are at high risk of progressing to severe COVID-19.
3 maj 2023 · What are the best treatments for covid-19? Written in cooperation with the World Health Organization, The BMJ’s living systematic review is a meta-analysis comparing the effects of treatments for covid-19,1 using data from more than 400 randomised clinical trials worldwide.
22 kwi 2022 · Today, WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date.
19 kwi 2023 · The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to develop therapeutic strategies that target severe acute respiratory syndrome coronavirus 2...
27 paź 2021 · One possible solution is a monoclonal antibody that neutralizes SARS-CoV-2 by targeting an evolutionarily conserved epitope that lies outside the rapidly evolving receptor-binding motif.
13 cze 2024 · Getting vaccinated against COVID-19 as soon as it’s your turn is the best way to reduce your risk of contracting the disease or developing severe symptoms.
